Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones

US8846693B2 · kind B2 · utility

Assignee

• INTRA-CELLULAR THERAPIES, INC. · US

Inventors

• Peng Li · New York, US
• Jun Zhao · New York, US
• Hailin Zheng · Teaneck, US

Key dates

• Filing date: Dec 6, 2008
• Grant date: Sep 30, 2014
• Expiry date: Jun 28, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[1H,2H]-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful for the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction.